Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
1.
Hum Vaccin Immunother ; 14(2): 396-403, 2018 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-29211620

RESUMO

A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n = 3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n = 248 9vHPV and n = 248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated. Vaccine was administered as a 3-dose regimen (at Day 1 and Months 2 and 6), and adverse events (AEs) were monitored. The most common AEs were injection-site events (91.1% and 79.0% in prior qHPV vaccine recipients and young men, respectively), the majority of which were mild. Discontinuations due to an AE were rare (0.2% and 0.0% among prior qHPV vaccine recipients and young men, respectively). In young men, the AE profile of the 9vHPV vaccine was generally similar to that of the qHPV vaccine. Overall, the 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients and in young men, with an AE profile generally consistent with that previously reported with the broader clinical program.


Assuntos
Vacinas contra Papillomavirus/efeitos adversos , Vacinas contra Papillomavirus/imunologia , Adolescente , Adulto , Criança , Método Duplo-Cego , Feminino , Humanos , Masculino , Infecções por Papillomavirus/prevenção & controle , Vacinação/efeitos adversos , Adulto Jovem
2.
Obstet Gynecol ; 115(5): 962-968, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20410769

RESUMO

OBJECTIVE: To evaluate medical abortion as a treatment alternative for late first-trimester abortions and to evaluate the decrease in beta-hCG after abortion at 63-90 days of gestation. METHODS: All women received mifepristone 200 mg orally, followed by 800 micrograms misoprostol vaginally 48 hours later. Misoprostol was repeated every 3 hours orally, to a maximum of five doses if needed. A clinical examination including ultrasonography was performed 8-14 days after treatment. beta-hCG level was determined before treatment and at follow-up. RESULTS: A total of 254 pregnant women with gestational age 63 to 90 days were included. The successful termination rate was 91.7%. Surgical evacuation was carried out in 21 (8.3%) women. Most women (91.0%) found the method of treatment highly acceptable. The beta-hCG levels of women with successful termination had decreased more than 97.5% at follow-up. CONCLUSION: Medical abortion is an effective and acceptable method for termination of pregnancy in late first trimester.


Assuntos
Abortivos não Esteroides/administração & dosagem , Abortivos Esteroides/administração & dosagem , Aborto Induzido/métodos , Mifepristona/administração & dosagem , Misoprostol/administração & dosagem , Adolescente , Adulto , Estudos de Casos e Controles , Gonadotropina Coriônica Humana Subunidade beta/sangue , Feminino , Humanos , Pessoa de Meia-Idade , Gravidez , Primeiro Trimestre da Gravidez , Adulto Jovem
3.
J Eur Acad Dermatol Venereol ; 23(10): 1147-55, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19453788

RESUMO

BACKGROUND: Quadrivalent human papillomavirus (HPV types 6/11/16/18) L1 VLP vaccine is highly effective in preventing HPV 6/11/16/18-related cervical and external genital disease. Herein, we evaluated the impact of the quadrivalent HPV 6/11/16/18 L1 VLP vaccine on prevention of HPV-associated cervico-genital lesions in a broad population of sexually active European women. METHODS: Female subjects (N = 9265) aged 16-24 with four or fewer lifetime sexual partners were enrolled and randomized to quadrivalent HPV vaccine or placebo. Subjects underwent cervicovaginal sampling for HPV DNA detection. Papanicolaou testing and anti-HPV 6/11/16/18 serology testing was also performed. RESULTS: Vaccine efficacy against lesions representing immediate cervical cancer precursors (cervical intraepithelial neoplasia grade 2/3 or adenocarcinoma in situ) related to HPV 6/11/16/18 in the per-protocol population was 100.0%[95% confidence interval (95% CI), 89.8-100.0]. Efficacy against external genital lesions (vulvar or vaginal intraepithelial neoplasia, condyloma, vulvar or vaginal cancer) related to vaccine HPV types in the per-protocol European population was 99.0% (95% CI, 94.4-100.0). CONCLUSION: These data demonstrate that quadrivalent HPV 6/11/16/18 vaccination programs in 16- to 24-year-old European women can be beneficial. NCT0009252, NCT00092534, NCT00092495.


Assuntos
Adenocarcinoma/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Displasia do Colo do Útero/prevenção & controle , Neoplasias do Colo do Útero/prevenção & controle , Adolescente , Adulto , Feminino , Vacina Quadrivalente Recombinante contra HPV tipos 6, 11, 16, 18 , Humanos , Placebos , Ensaios Clínicos Controlados Aleatórios como Assunto , Parceiros Sexuais , Adulto Jovem
4.
Br J Cancer ; 95(11): 1459-66, 2006 Dec 04.
Artigo em Inglês | MEDLINE | ID: mdl-17117182

RESUMO

Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16-23 years) were enrolled in a randomised, placebo-controlled study of a quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine with vaccination at months 0, 2, and 6. At regular intervals through 3 years, subjects underwent gynaecologic examination, cervicovaginal sampling for HPV DNA, serum anti-HPV testing, and Pap testing, with follow-up biopsy as indicated. A subset of 241 subjects underwent two further years of follow-up. At 5 years post enrollment, the combined incidence of HPV 6/11/16/18-related persistent infection or disease was reduced in vaccine-recipients by 96% (two cases vaccine versus 46 placebo). There were no cases of HPV 6/11/16/18-related precancerous cervical dysplasia or genital warts in vaccine recipients, and six cases in placebo recipients (efficacy = 100%; 95% CI:12-100%). Through 5 years, vaccine-induced anti-HPV geometric mean titres remained at or above those following natural infection. In conclusion, a prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18. This duration supports vaccination of adolescents and young adults, which is expected to greatly reduce the burden of cervical and genital cancers, precancerous dysplasia, and genital warts.


Assuntos
Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/imunologia , Vacinas contra Papillomavirus/uso terapêutico , Neoplasias do Colo do Útero/prevenção & controle , Vírion/imunologia , Adolescente , Adulto , Alphapapillomavirus/imunologia , Anticorpos Antivirais/sangue , Condiloma Acuminado/prevenção & controle , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Incidência , Infecções por Papillomavirus/epidemiologia , Displasia do Colo do Útero/prevenção & controle , Esfregaço Vaginal
5.
Br J Cancer ; 92(5): 895-905, 2005 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-15726105

RESUMO

Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have characterised the C system in the intraperitoneal ascitic fluid (AF) from ovarian cancer patients. Most of the AF samples showed alternative and classical pathway haemolytic activity. The levels of C3 and C4 were similar to or in the lower normal range when compared to values in normal sera, respectively. However, elevated levels of C3a and soluble C5b-9 suggested C activation in vivo. Malignant cells isolated from the AF samples had surface deposits of C1q and C3 activation products, but not of C5b-9 (the membrane attack complex; MAC). Activation could have become initiated by anti-tumour cell antibodies that were detected in the AFs and/or by changes on tumour cell surfaces. The lack of MAC was probably due to the expression of C membrane regulators CD46, CD55 and CD59 on the tumour cells. Soluble forms of C1 inhibitor, CD59 and CD46, and the alternative pathway inhibitors factor H and FHL-1 were present in the AF at concentrations higher than in serum samples. Despite the presence of soluble C inhibitors it was possible to use AF as a C source in antibody-initiated killing of ovarian carcinoma cells. These results demonstrate that although the ovarian ascitic C system fails as an effective immunological surveillance mechanism, it could be utilised as an effector mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C regulators are neutralised.


Assuntos
Ascite/fisiopatologia , Proteínas do Sistema Complemento/metabolismo , Neoplasias Ovarianas/fisiopatologia , Adenocarcinoma/sangue , Adenocarcinoma/fisiopatologia , Adulto , Idoso , Anticorpos Monoclonais , Ascite/sangue , Antígenos CD59/sangue , Linhagem Celular Tumoral , Complemento C3/metabolismo , Complemento C4/metabolismo , Feminino , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Pessoa de Meia-Idade , Neoplasias Ovarianas/sangue
6.
Int J Gynecol Cancer ; 14(5): 957-65, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15361209

RESUMO

Studies, to date, have suggested that there are distinct molecular differences between microsatellite stable (RER(-)) and unstable (RER(+)) solid tumors, such as colorectal carcinoma. We investigated a range of molecular events including mutation frequency of K-ras, microsatellite instability within the coding region of TGF-beta RII, BAX, and IGF-IIR, loss of expression of p53, hMLH1, hMSH2, hMSH6, and PTEN, and methylation of hMLH1, hMSH2, and PTEN within a large population-based series of sporadic endometrial carcinomas to establish whether there are distinct differences between replication error repair (RER(+)) and RER(-) cases. RER(+) endometrial carcinomas tended to be diploid with normal p53 expression, compared with RER(-) cases. Mutations in TGF-beta RII, IGF-IIR, and BAX were rare, but there was a strong association between mutation and RER(+) status. Methylation and loss of hMLH1 expression were significantly more common in RER(+) cases, as was methylation of PTEN. K-ras mutations were equally frequent in RER(+) and RER(-) cases. Despite the absence of distinct clinicopathological differences between RER(+) and RER(-) cases in this series of sporadic endometrial carcinomas, our results confirm that there are molecular differences between RER(+) and RER(-) cases, but the molecular events occurring in RER(+) endometrial carcinomas differ from those seen in RER(+) colorectal carcinomas.


Assuntos
Carcinoma/genética , Neoplasias do Endométrio/genética , Genes ras , Repetições de Microssatélites/genética , Proteínas Adaptadoras de Transdução de Sinal , Pareamento Incorreto de Bases , Carcinoma/patologia , Proteínas de Transporte , Metilação de DNA , Análise Mutacional de DNA , Reparo do DNA , Neoplasias do Endométrio/patologia , Feminino , Humanos , Imuno-Histoquímica , Proteína 1 Homóloga a MutL , Proteínas de Neoplasias , Proteínas Nucleares
7.
Eur J Anaesthesiol ; 21(10): 776-80, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15678731

RESUMO

BACKGROUND AND OBJECTIVE: In 1991 general anaesthesia was used extensively for emergency Caesarean section at Haukeland University Hospital even in patients with an ongoing epidural infusion. With increased knowledge of the potential safety benefits of regional anaesthesia and increased experience with the technique, we decided to use indwelling epidural catheters for emergency Caesarean section. METHODS: We conducted a retrospective analysis of a full annual data set on emergency Caesarean section in parturients with ongoing epidural analgesia in 1997 and compared it with a similar data set from 1991. RESULTS: Epidural anaesthesia was used significantly more often in 1997 with 115 (78%) cases than in 1991 with five (12%) cases (P < 0.001). Elapsed time before adequate anaesthesia and the start of surgery was significantly shorter in 1991 (mean 8.3 min) compared to 1997 (mean 13 min) (P < 0.001). No deaths or major complications were observed in either group. Intraoperative minor complications were observed more frequently in 1997 with 70 cases (47%) than in 1991 with two cases (6%) (P < 0.001). The principal complications were hypotension and nausea. Postoperative complications in mother and neonate were similar in both groups. There was a significantly shorter mean hospital stay in 1997 (6 days), compared with 1991 (8 days) (P < 0.001). CONCLUSION: The increase in the use of indwelling epidural catheters for emergency Caesarean section has resulted in a significant increase in the use of regional anaesthesia. A modest increase in time elapsed before start of surgery was observed although there were no significant differences in the number of neonates with low Apgar scores. No major complications were observed, but there was an increased frequency of minor complications in 1997.


Assuntos
Anestesia Epidural , Anestesia Obstétrica , Cesárea , Analgesia Epidural , Anestesia Epidural/efeitos adversos , Anestesia Obstétrica/efeitos adversos , Índice de Apgar , Cateteres de Demora , Emergências , Feminino , Humanos , Gravidez
8.
Tidsskr Nor Laegeforen ; 121(28): 3286-91, 2001 Nov 20.
Artigo em Norueguês | MEDLINE | ID: mdl-11826459

RESUMO

BACKGROUND: Antiprogestins, agents that inhibit the action of progesterone, are among the most controversial and yet the more interesting therapeutic compounds developed over the past 20 years. MATERIAL AND METHODS: We present a review of the literature identified through limited searches on Medline, Cochrane and the Internet, with a discussion of the biological, clinical, political and ethical aspects of this important drug. RESULTS: The first effective antiprogestin in clinical use was mifepristone (also known as RU 486). This agent provides the most effective and safest means of medical abortion. It may also be used as a contraceptive and delivery-inducing agent and in the treatment of spontaneous abortion, ectopic pregnancies, leiomyoma, endometriosis, intrauterine fetal death, Cushing's syndrome and progesterone-dependent malignancies. INTERPRETATION: The introduction of mifepristone as an abortion-inducing agent has created intense political, ethical and moral controversies which have delayed clinical investigations and evaluations for potential expanded use.


Assuntos
Abortivos Esteroides , Anticoncepcionais Orais Sintéticos , Antagonistas de Hormônios , Mifepristona , Abortivos Esteroides/administração & dosagem , Abortivos Esteroides/química , Abortivos Esteroides/história , Anticoncepcionais Orais Sintéticos/administração & dosagem , Anticoncepcionais Orais Sintéticos/história , Feminino , Doenças dos Genitais Femininos/tratamento farmacológico , História do Século XX , Antagonistas de Hormônios/administração & dosagem , Antagonistas de Hormônios/história , Humanos , Trabalho de Parto Induzido , Mifepristona/administração & dosagem , Mifepristona/química , Mifepristona/história , Neoplasias/tratamento farmacológico , Gravidez , Complicações na Gravidez/tratamento farmacológico , Receptores de Progesterona/efeitos dos fármacos
10.
Tidsskr Nor Laegeforen ; 120(23): 2749-54, 2000 Sep 30.
Artigo em Norueguês | MEDLINE | ID: mdl-11107918

RESUMO

BACKGROUND: Previous studies on effects of rehabilitation programmes for women with breast cancer are rare, but promising. This study aimed to examine the physical and psychological conditions for these patients before and after a rehabilitation programme at Red Cross Haugland Rehabilitation Centre in Norway. MATERIAL AND METHODS: Included in the study were a total of 50 women, aged 31-66 (mean 49) years, who had undergone surgical treatment, chemotherapy and radiation therapy for cancer mammae stage 1 and 2 (limited to the breast only or spread to the axillary lymph nodes, respectively). They received a three-week rehabilitation programme, followed by a three-month period at home and a one-week follow-up at the rehabilitation centre. Examinations of physical and psychological status were performed before and after the three-week stay and at follow-up. RESULTS: Maximum oxygen uptake increased from 67% to 77% of predicted value, the mental status and subjective rating of life quality improved, the physical activity level increased, and 36 out of 46 subjects returned to their jobs during the three-month follow-up. The women themselves reported subjective positive effects of participating in the programme. INTERPRETATION: Although the present study was non-controlled, the positive results were so promising that further controlled studies should be encouraged, as well as rehabilitation programmes for women with breast cancer.


Assuntos
Neoplasias da Mama/reabilitação , Qualidade de Vida , Fatores Socioeconômicos , Adulto , Idoso , Neoplasias da Mama/psicologia , Neoplasias da Mama/cirurgia , Feminino , Seguimentos , Humanos , Saúde Mental , Pessoa de Meia-Idade , Noruega , Participação do Paciente , Satisfação do Paciente , Exame Físico , Aptidão Física , Escalas de Graduação Psiquiátrica , Programas Médicos Regionais , Licença Médica , Inquéritos e Questionários , Serviços de Saúde da Mulher/normas
11.
Clin Cancer Res ; 6(10): 4026-32, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11051252

RESUMO

Normal endometrium, an estrogen-responsive tissue, expresses the estrogen receptor (ER) alpha gene. Loss of ER expression, the basis for which is currently unknown, is often seen in advanced stage, poor prognosis endometrial tumors. The ER gene undergoes de novo methylation with high frequency in a wide variety of human tumors, including ER-negative breast cancers. In this study, we used several bisulfite-based detection methods to assess whether loss of ER positivity in endometrial tumors is associated with aberrant methylation of the ER gene. Although extensive methylation of a 600-bp region at the 5' end of the gene was seen in two endometrial carcinoma cell lines, none of the 55 CpGs in this region was methylated in 25 of 26 ER-deficient endometrial carcinomas.


Assuntos
Metilação de DNA , Neoplasias do Endométrio/metabolismo , Receptores de Estrogênio/biossíntese , Receptores de Estrogênio/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Ilhas de CpG/genética , Endométrio/metabolismo , Feminino , Humanos , Pessoa de Meia-Idade , Modelos Genéticos , Análise de Sequência de DNA , Sulfitos/metabolismo
12.
Clin Cancer Res ; 6(9): 3607-13, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10999752

RESUMO

Microsatellite instability (MSI) is a characteristic feature of hereditary nonpolyposis colorectal cancer and is also observed in sporadic colorectal and endometrial cancers. Alterations in the mismatch repair genes hMLH1 and hMSH2 are important for the development of MSI. It has recently been demonstrated that hypermethylation of the hMLH1 promoter region is associated with MSI and appears to be a common mechanism for gene inactivation. For endometrial carcinoma, however, previous studies have been relatively small and have not been population based. We therefore wanted to assess the frequency and prognostic significance of hypermethylation of the hMLH1 and hMSH2 genes in conjunction with hMLH1 protein expression in a prospective and population-based series of endometrial carcinoma patients with known MSI status and complete follow-up. A total of 138 patients were studied, and methylation of hMLH1 was found in 23% of tumors with conclusive results, whereas methylation of hMSH2 was seen in only 1% of tumors. Methylation of hMLH1 was significantly correlated with MSI (P < 0.001). Loss of nuclear staining of hMLH1 protein was seen in 14% of the cases and was significantly correlated with hMLH1 methylation and MSI (P < 0.001). Normal expression of hMLH1 was seen in all of the unmethylated tumors (100%). Of the 14 MSI-positive tumors that were also methylated, all but 1 (93%) showed a loss of nuclear expression of hMLH1. None of the tumors with loss of hMLH1 expression or hMLH1 methylation were aneuploid (P for both < or = 0.05), and loss of hMLH1 expression and hMLH1 methylation was significantly correlated with lack of p53 overexpression (P for both < or = 0.05). Nuclear hMLH1 staining and hMLH1 methylation did not significantly influence survival. In conclusion, hMLH1 methylation was common and was significantly correlated with loss of hMLH1 protein expression, MSI, diploid tumors, and lack of p53 overexpression. In contrast, hMSH2 methylation was infrequent in this prospective and population-based series of endometrial carcinomas.


Assuntos
Metilação de DNA , Proteínas de Ligação a DNA , Neoplasias do Endométrio/genética , Proteínas de Neoplasias/genética , Proteínas Adaptadoras de Transdução de Sinal , Pareamento Incorreto de Bases , Proteínas de Transporte , Núcleo Celular/metabolismo , Reparo do DNA , Neoplasias do Endométrio/metabolismo , Feminino , Humanos , Repetições de Microssatélites/genética , Proteína 1 Homóloga a MutL , Proteína 2 Homóloga a MutS , Proteínas de Neoplasias/biossíntese , Proteínas Nucleares , Reação em Cadeia da Polimerase , Prognóstico , Regiões Promotoras Genéticas , Estudos Prospectivos , Proteínas Proto-Oncogênicas/biossíntese , Proteínas Proto-Oncogênicas/genética
13.
Cancer Res ; 60(6): 1750-2, 2000 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-10749149

RESUMO

The replication error repair (RER) phenotype has been reported in 9-43% of sporadic endometrial carcinomas, but there are conflicting data about its effect on prognosis in this disease. This study was performed to establish the frequency of the RER phenotype and to determine its effect on prognosis in a population-based series of 259 endometrial carcinomas with long-term follow-up. Five mononucleotide and dinucleotide microsatellite markers on different chromosomes were analyzed, and tumors exhibiting microsatellite instability at two or more loci were classified as RER+. A total of 116 of 259 tumors (45%) were RER+. The 5-year survival rate for the RER- group was 76.2% compared with 79.6% for RER+ cases (P = 0.6). The 5-year recurrence-free survival rate among the 228 patients surgically treated for cure was 80.6% in the RER- group compared with 83.6% in the RER+ group (P = 0.6). The analysis indicates that the RER phenotype is common in endometrial carcinomas, but there is no association with prognosis in this large population-based series of endometrial carcinomas.


Assuntos
Neoplasias do Endométrio/genética , Repetições de Microssatélites/genética , Idoso , Alelos , Estudos de Coortes , DNA/genética , Dano ao DNA , Reparo do DNA , Replicação do DNA , Neoplasias do Endométrio/mortalidade , Neoplasias do Endométrio/patologia , Feminino , Seguimentos , Frequência do Gene , Humanos , Pessoa de Meia-Idade , Mutação , Fenótipo , Prognóstico , Análise de Sobrevida , Taxa de Sobrevida
14.
J Clin Oncol ; 17(5): 1382-90, 1999 May.
Artigo em Inglês | MEDLINE | ID: mdl-10334522

RESUMO

PURPOSE: For endometrial carcinoma patients, there is a need for improved identification of high-risk groups that may benefit from postoperative adjuvant therapy. We therefore studied the prognostic impact of markers for cell proliferation, cell-cycle regulation, and angiogenesis among endometrial carcinoma patients in a population-based setting. PATIENTS AND METHODS: All patients diagnosed with endometrial carcinoma between 1981 and 1985 in Hordaland County, Norway, were studied. The median follow-up for the survivors was 11.5 years (range, 8 to 15 years), with no patient lost because of insufficient follow-up information. Paraffin-embedded tumor tissue, available in 96% of the cases (n = 142), was studied immunohistochemically for microvessel density (MVD) and expression of Ki-67, p53, and p21 proteins. We used the hot spot method for calculation of MVD, and expression of Ki-67 and p21 protein, because this approach may increase the probability of detecting small aggressive clones of possible prognostic relevance. The importance of these tumor markers was investigated in univariate survival analyses and Cox regression analysis. RESULTS: The majority of traditional clinicopathologic variables was significantly associated with the tumor biomarkers. Age, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type, histologic grade, MVD, as well as Ki-67, p53, and p21 protein expression, all significantly influenced survival in univariate analyses (P < or = .05). In the Cox regression analysis, age, FIGO stage, MVD, Ki-67 expression, and p53 expression were the only variables with independent prognostic impact (P < or = .05), whereas histologic type, histologic grade, and p21 expression had no independent influence. A group of high-risk patients with more than one unfavorable marker was identified. CONCLUSION: In addition to age and FIGO stage, MVD, Ki-67, and p53 protein expression showed an independent prognostic impact. Thus, information derived from routine histologic specimens identified a subgroup of high-risk endometrial carcinoma patients in this population-based study.


Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias do Endométrio/irrigação sanguínea , Neoplasias do Endométrio/metabolismo , Neovascularização Patológica/patologia , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Inibidor de Quinase Dependente de Ciclina p21 , Ciclinas/metabolismo , Neoplasias do Endométrio/mortalidade , Neoplasias do Endométrio/patologia , Feminino , Seguimentos , Humanos , Antígeno Ki-67/metabolismo , Pessoa de Meia-Idade , Invasividade Neoplásica , Estadiamento de Neoplasias , Prognóstico , Modelos de Riscos Proporcionais , Taxa de Sobrevida , Proteína Supressora de Tumor p53/metabolismo
15.
Clin Cancer Res ; 4(11): 2779-85, 1998 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9829742

RESUMO

For patients with localized endometrial carcinoma at primary operation, there is a definite need for more specific prognostic parameters to select patients for adjuvant therapy. The purpose of this study was to evaluate the applicability and prognostic significance of markers for tumor cell proliferation (S phase fraction and Ki-67 expression) among endometrial carcinoma patients, relative to the information derived from established clinicopathological variables including DNA and receptor analyses. In a prospective study of 115 patients treated for endometrial carcinoma, fresh tumor tissue was collected for assessments of ploidy, S phase fraction and hormone receptor concentrations. Ki-67 expression was assessed immunohistochemically on sections from formalin-fixed and paraffin-embedded tumor specimens. These variables were examined together with traditional clinicopathological features in univariate and multivariate (Cox proportional hazards regression model) survival analyses. The median follow-up time for the survivors was 9 years (range, 5-15), with no patient lost due to insufficient follow-up information. The expression of Ki-67 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.0004), histological type (P = 0.03), and histological grade (P = 0.0001). S phase fraction was significantly associated with histological grade (P = 0.02), whereas the association with histological type was of borderline significance (P = 0.07). In univariate analyses, survival was significantly influenced by FIGO stage (P <0.0001), histological type (P = 0.0002), histological grade (P = 0.002), ploidy (P = 0.015), S phase fraction (P = 0.017), progesterone receptor concentration (P = 0.02), and Ki-67 expression (P <0.0001). In Cox regression analysis, FIGO stage (hazard ratio, 11.7; 95% confidence interval, 4.3-32.1) and Ki-67 (hazard ratio, 8.7; 95% confidence interval, 3.0-25.2) were the only variables with independent prognostic impact. When patients whose tumors were confined to the uterus were analyzed separately, Ki-67 was the only variable with an independent prognostic importance. Ki-67 expression was superior to S phase fraction both in applicability and prognostic value. FIGO stage and Ki-67 expression were the only variables with independent prognostic impact in Cox regression analysis. Ki-67 expression is assessed on the histological specimens taken routinely, with no separate sampling technique; this should make it easy to use in a routine setting.


Assuntos
Biomarcadores Tumorais/análise , Neoplasias do Endométrio/metabolismo , Antígeno Ki-67/análise , Neoplasias Ovarianas/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos Nucleares , Biomarcadores Tumorais/biossíntese , Neoplasias do Endométrio/diagnóstico , Estudos de Avaliação como Assunto , Feminino , Seguimentos , Humanos , Imuno-Histoquímica , Antígeno Ki-67/biossíntese , Pessoa de Meia-Idade , Proteínas Nucleares/análise , Neoplasias Ovarianas/diagnóstico , Prognóstico , Estudos Prospectivos , Análise de Regressão , Fatores de Risco , Fase S/fisiologia , Análise de Sobrevida
16.
Cancer ; 83(5): 956-64, 1998 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-9731900

RESUMO

BACKGROUND: The identification of high risk patients with endometrial carcinoma is considered essential for individualized therapy to improve prognosis and avoid overtreatment. The goal of the current study was to investigate the prognostic value of nuclear morphometry, particularly for patients with localized endometrial carcinoma. METHODS: In a prospective study including 115 patients primarily treated for endometrial carcinoma at Haukeland University Hospital in Bergen, Norway between 1981-1990, data regarding clinical variables, histologic type, histologic grade, DNA index, estrogen and progesterone receptor concentration and nuclear morphometry were collected. The median follow-up period for the survivors was 9 years (range, 5-15 years). RESULTS: International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type, histologic grade (World Health Organization), DNA index, progesterone receptor concentration, mean nuclear area, greatest and smallest nuclear diameter, nuclear perimeter, and standard deviation to mean nuclear area all influenced survival significantly in univariate analyses. In multivariate analyses, FIGO stage and morphometrically determined mean nuclear size were identified as independent prognostic factors, whereas histologic grade had borderline significance. Histologic type, DNA index, progesterone receptor concentration, and standard deviation of mean nuclear area were not significantly associated with prognosis. The nuclear perimeter was identified as the most powerful prognostic morphometric factor, and in a separate multivariate analysis that included patients with localized disease only, it was also an independent prognostic factor. This also was the case for the subgroup of patients with endometrioid carcinoma, adenoacanthoma, or adenosquamous carcinoma. CONCLUSIONS: Morphometric nuclear grade was a stronger prognostic factor than subjective histologic grade, histologic type, DNA index, and hormone receptor concentration in endometrial carcinoma patients, including those patients with localized disease.


Assuntos
Carcinoma/patologia , Núcleo Celular/patologia , Neoplasias do Endométrio/patologia , Adenocarcinoma/mortalidade , Adenocarcinoma/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma/mortalidade , Carcinoma Adenoescamoso/mortalidade , Carcinoma Adenoescamoso/patologia , DNA de Neoplasias/análise , Neoplasias do Endométrio/mortalidade , Feminino , Humanos , Metaplasia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Receptores de Progesterona/análise , Estudos Retrospectivos
17.
Br J Cancer ; 77(7): 1140-4, 1998 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9569052

RESUMO

Angiogenesis is thought to be an important factor for tumour growth and metastatic spread, and microvessel counts may provide useful prognostic information for several tumour types. To investigate the prognostic impact of angiogenesis in endometrial carcinoma patients, the intratumour microvessel density, which was determined immunohistochemically, has been related to survival. Sixty patients with endometrial carcinoma with long (median 19 years) and complete follow-up have been studied. Patients with increased mean microvessel density (MVDmean > 68 mm2) had a significantly shorter 5-year survival compared with the rest (57% vs 90%, P = 0.004). In multivariate survival analyses, MVDmean had an independent prognostic impact (P = 0.03) when FIGO stage, histological type, histological grade as well as nuclear p53 protein expression was adjusted for. These findings indicate that intratumour microvessel density may contribute additional prognostic information to that obtained from the known risk factors and may be helpful in identifying endometrial carcinoma patients at high risk for disease progression.


Assuntos
Carcinoma/irrigação sanguínea , Neoplasias do Endométrio/irrigação sanguínea , Neovascularização Patológica/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Análise de Sobrevida
18.
Cancer ; 82(7): 1328-33, 1998 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-9529025

RESUMO

BACKGROUND: Several epidemiologic studies have shown an inverse relationship between parity and the incidence of endometrial carcinoma. A prognostic influence of reproductive factors has been reported for carcinomas of the breast and uterine cervix; but no such independent influence has been reported for endometrial carcinoma, to the authors' knowledge. Therefore, the authors investigated the prognostic importance of parity in an unselected group of patients. METHODS: Clinical and histopathologic data on all 316 patients treated for endometrial carcinoma during the period 1981-1990 in Hordaland County, Norway, were related to cause specific death in univariate (Kaplan-Meier) and multivariate (Cox proportional hazards regression model) analyses. The median follow-up for the survivors was 9 years (range, 4-16 years). No patients were lost due to insufficient follow-up information. RESULTS: Nulliparous women had a poorer 5-year survival rate compared with patients who had had 1 or more deliveries (57% vs. 81%, P = 0.0001), and they were significantly older and had more advanced disease at the time of primary surgery than the parous women. After adjustment for traditional risk factors, a hazard ratio of 2.81 (95% confidence interval, 1.55-5.06) was found for nulliparous versus parous women. International Federation of Gynecology and Obstetrics stage, curative treatment, and tumor differentiation grade were also identified as independent prognostic factors, whereas age and menopausal status had prognostic significance in the univariate analysis only. CONCLUSIONS: The decreased survival among nulliparous women reported herein may reflect biologic differences between parous and nulliparous endometrial carcinoma patients. It may also be due in part to a greater delay in diagnosing the women in the nulliparous group.


Assuntos
Neoplasias do Endométrio/mortalidade , Paridade , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Endométrio/diagnóstico , Feminino , Humanos , Menopausa , Pessoa de Meia-Idade , Análise Multivariada , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida
19.
Br J Obstet Gynaecol ; 104(11): 1302-7, 1997 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9386033

RESUMO

OBJECTIVE: To identify women treated for endometrial carcinoma with increased risk for recurrent disease, to examine how and when recurrences are discovered, and to assess the clinical benefit of routine follow up investigations. DESIGN: Retrospective case analysis. SETTING: Hordaland county, Norway. POPULATION: All women treated for endometrial carcinoma in a demographically well defined area, in a 10-year period (1981-1990). METHODS: Data concerning patient characteristics and course of the disease were collected through review of the medical records, correspondence with the primary physician and from the Norwegian Cancer Registry. Univariate and multivariate survival analysis. RESULTS: After curative surgical treatment 249 women diagnosed with endometrial carcinoma were followed for a median period of 9 years (range 4-16) or until death. Among these 249 radically treated patients, 47 had recurrent disease, 32 within the first two years. Ten of the recurrences were diagnosed at routine follow up, but only four were asymptomatic. In our follow up programme, one asymptomatic recurrence was detected for every 653 routine consultations. A low risk group, with FIGO Stage IA/IB or patient age below 60 years at primary operation was identified in multivariate recurrence-free survival analysis. No asymptomatic recurrences were found in this group. CONCLUSIONS: Low risk women should be considered for an alternative, less frequent follow up. The sensitivity for current practice of routine follow up in detecting asymptomatic recurrences is so low that other beneficial effects should be documented to defend the large resources spent on this programme.


Assuntos
Neoplasias do Endométrio/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Cuidados Pós-Operatórios , Estudos Retrospectivos , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento
20.
Artigo em Inglês | MEDLINE | ID: mdl-9219459

RESUMO

BACKGROUND: The purpose of this study was to examine if placentas of small- for-gestational-age (SGA) and non-SGA infants differ with respect to proliferative cell activity. METHOD: Cell cycle distribution was studied in placentas from 181 SGA (birthweight < 10th percentile) and 528 non-SGA births by flow cytometry measurements of relative DNA content. RESULTS: The fraction of cells in various cell cycle phases (G1-, S- and G2-phases) did not differ with gestational age from 30 to 43 weeks in either of the groups. The placentas of the SGA infants had a significantly lower mean (+/-1 SEM) growth fraction than placentas of non-SGA infants (S-phase 5.2 +/- 0.2 vs 5.5 +/- 0.1, p = 0.05, and G2-fraction 5.4 +/- 0.2 vs 6.3 +/- 0.1, p < 0.001), but the overlaps of the distributions were large. Thus sensitivity, specificity and predictive values of low fractions did not differ substantially-from a purely random prediction of SGA. CONCLUSIONS: Cell division in the placenta is maintained until and beyond term. Placentas of SGA infants have on average, lower proliferative activity than placentas of non-SGA infants, but the difference is too small to be of predictive value in identifying intrauterine growth retardation.


Assuntos
Retardo do Crescimento Fetal/patologia , Recém-Nascido Pequeno para a Idade Gestacional , Placenta/patologia , Adulto , Biópsia , Divisão Celular , DNA/análise , Feminino , Retardo do Crescimento Fetal/epidemiologia , Retardo do Crescimento Fetal/etiologia , Citometria de Fluxo , Humanos , Recém-Nascido , Masculino , Noruega/epidemiologia , Valor Preditivo dos Testes , Gravidez , Estudos Prospectivos , Sensibilidade e Especificidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA